Candel's CAN-2409 Shows Significant Survival Extension, Two-Fold mOS Improvement in Advanced NSCLC
CADL sits 20% above its 52-week low of $4.25.
Summary
Candel Therapeutics announced significantly improved and extended survival data for its investigational therapy, aglatimagene besadenovec (CAN-2409), in patients with advanced non-small cell lung cancer (NSCLC) who had an inadequate response to prior immune checkpoint inhibitors. The updated data showed a two-fold improvement in median overall survival (mOS) compared to historical controls (21.5-25.4 months vs. 9.8-11.8 months) and an increase in 24-month survival from 39% to 50% in the per-protocol population. This positive update builds upon the "strong Phase 2a NSCLC results" mentioned in the company's recent 10-K filing on March 12, 2026, providing more detailed and even more favorable long-term follow-up data. The substantial improvement in survival, particularly in a difficult-to-treat patient population with limited options, represents a significant de-risking event for CAN-2409 and Candel Therapeutics. This data strengthens the drug's potential as a novel therapeutic approach and could significantly enhance its commercial prospects and accelerate its development pathway. Investors will now be watching for further updates on the company's plans to advance CAN-2409 into a Phase 3 trial, as indicated by previous statements, and any potential regulatory interactions or partnership opportunities that may arise from these compelling results.
At the time of this announcement, CADL was trading at $5.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $365.5M. The 52-week trading range was $4.25 to $9.08. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.